The Perfect Enemy | Category: Social Impact | Page 343
July 17, 2025

Social Impact

Kinarus Therapeutics Announces Discontinuation of the Phase 2 KINETIC Study of KIN001 in Hospitalized COVID-19 Patients Following a Prespecified Interim Analysis of Efficacy and Safety

Kinarus Therapeutic Holding AGKINETIC, a Phase 2 clinical study of KIN001, an oral drug combination, to be discontinued following recommendation...